Abstract
Objective: To assess HIV-1 isolate based resistance profiles from extensively pretreated patients and effects of a resistance guided switch of antiretroviral therapy.
Methods: In a prospective study phenotypic and genotypic resistance analyses were performed on HIV infected individuals with failure of the current therapy and history of at least three antiretroviral regimens. Antiretroviral therapy was changed according to the results. Viral load and CD4 lymphocyte counts were measured at baseline, after 10 (SD 2), and 24 (2) weeks.
Results: All patients (n=52) failed their actual regimen. Currently versus ever previously taking the specific drug, resistance associated mutations and phenotypic resistance to AZT and 3TC were found in over 80% of individuals; resistance to DDI and D4T was detected in less than 10% of cases. A resistance guided switch of therapy was followed by a median decrease of viral load of 0.5 log10 units after 24 weeks. Individuals resistant to two or more drugs compared with patients with resistance to less than two drugs of ongoing treatment, were switched to a regimen containing DDI, D4T, and a PI or NNRTI. After 10 (SD 2) weeks viral load decrease was pronounced in patients with resistance to at least two drugs in the previous regimen.
Conclusions: Among different RTI, the profile of clinically relevant resistance indicates pronounced differences when looking at separate drugs. Regarding virological response, in the context of available drugs, resistance tested with currently used methods is of limited value in extensively pretreated patients and seems to have its value primarily in first or second switch of therapy.
Key Words: HIV drug resistance; antiretroviral therapy; HIV diagnostic tests
Full Text
The Full Text of this article is available as a PDF (113.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boucher C. A. HIV drug resistance tests are here to stay. Curr Opin Infect Dis. 1999 Feb;12(1):27–32. doi: 10.1097/00001432-199902000-00005. [DOI] [PubMed] [Google Scholar]
- Coakley E. P., Gillis J. M., Hammer S. M. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS. 2000 Jan 28;14(2):F9–15. doi: 10.1097/00002030-200001280-00002. [DOI] [PubMed] [Google Scholar]
- Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C. A., Schapiro J. M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999 Jun 26;353(9171):2195–2199. doi: 10.1016/s0140-6736(98)12291-2. [DOI] [PubMed] [Google Scholar]
- Hertogs K., de Béthune M. P., Miller V., Ivens T., Schel P., Van Cauwenberge A., Van Den Eynde C., Van Gerwen V., Azijn H., Van Houtte M. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother. 1998 Feb;42(2):269–276. doi: 10.1128/aac.42.2.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holguín A., Dietrich U., Immelmann A., Soriano V. Genotypic and phenotypic resistance to stavudine after long-term monotherapy. BMS-020 Spanish Study Group. Antivir Ther. 1998;3(3):183–186. [PubMed] [Google Scholar]
- Moore K. H., Barrett J. E., Shaw S., Pakes G. E., Churchus R., Kapoor A., Lloyd J., Barry M. G., Back D. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS. 1999 Nov 12;13(16):2239–2250. doi: 10.1097/00002030-199911120-00006. [DOI] [PubMed] [Google Scholar]
- Palella F. J., Jr, Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853–860. doi: 10.1056/NEJM199803263381301. [DOI] [PubMed] [Google Scholar]
- Paris D., Ledergerber B., Weber R., Jost J., Flepp M., Opravil M., Ruef C., Zimmerli S. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses. 1999 Dec 10;15(18):1631–1638. doi: 10.1089/088922299309676. [DOI] [PubMed] [Google Scholar]
- Pellegrin I., Izopet J., Reynes J., Denayrolles M., Montes B., Pellegrin J. L., Massip P., Puel J., Fleury H., Segondy M. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS. 1999 Sep 10;13(13):1705–1709. doi: 10.1097/00002030-199909100-00014. [DOI] [PubMed] [Google Scholar]
- Salomon H., Montaner J. S., Belmonte A., Wainberg M. A. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase. Antivir Ther. 1998;3(3):177–182. [PubMed] [Google Scholar]
- Shafer R. W., Winters M. A., Palmer S., Merigan T. C. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med. 1998 Jun 1;128(11):906–911. doi: 10.7326/0003-4819-128-11-199806010-00008. [DOI] [PubMed] [Google Scholar]
- Staszewski S., Miller V., Sabin C., Berger A., Hill A. M., Phillips A. N. Rebound of HIV-1 viral load after suppression to very low levels. AIDS. 1998 Dec 3;12(17):2360–2360. [PubMed] [Google Scholar]
- Zöllner B., Feucht H. H., Weitner L., Adam A., Laufs R. Drug-resistant genotyping in HIV-1 therapy. Lancet. 1999 Sep 25;354(9184):1120–1121. doi: 10.1016/s0140-6736(05)76910-5. [DOI] [PubMed] [Google Scholar]